Literature DB >> 17904982

Metabolic score as a novel approach to assessing preeclampsia risk.

Rebecca M Mazar1, Sindhu K Srinivas, Mary D Sammel, Christina M Andrela, Michal A Elovitz.   

Abstract

OBJECTIVE: Clinical trials have confirmed the association of metabolic syndrome with cardiovascular disease (CVD) in women. Because recent evidence suggests that preeclampsia is a risk factor for future CVD, we sought to determine whether metabolic syndrome was associated with preeclampsia. STUDY
DESIGN: As part of a large case-control study, women were prospectively identified with preeclampsia. Controls were patients presenting for delivery at term without preeclampsia. Two pregnancy-based metabolic scores (0, 1, or 2 or more) were created using initial or final pregnancy body mass index, chronic hypertension, and diabetes. Stratified analysis and logistic regression were used to evaluate the association of metabolic score with preeclampsia and disease severity.
RESULTS: For initial metabolic score, 44.1%, 42.3%, and 13.5% of cases (n = 259) and 61.5%, 33.2%, and 5.3% of controls (n = 297) had scores of 0, 1 (odds ratio [OR] 1.91, P = .002), and 2 or more (OR 2.65, P = .001), respectively.
CONCLUSION: Metabolic score appears to be associated independently with developing preeclampsia, particularly severe disease.

Entities:  

Mesh:

Year:  2007        PMID: 17904982     DOI: 10.1016/j.ajog.2007.07.014

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study.

Authors:  Piya Chaemsaithong; Roberto Romero; Adi L Tarca; Steven J Korzeniewski; Alyse G Schwartz; Jezid Miranda; Ahmed I Ahmed; Zhong Dong; Sonia S Hassan; Lami Yeo; Tinnakorn Tinnakorn
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-29

2.  Clinical factors associated with readmission for postpartum hypertension in women with pregnancy-related hypertension: a nested case control study.

Authors:  A Hirshberg; L D Levine; S K Srinivas
Journal:  J Perinatol       Date:  2016-01-14       Impact factor: 2.521

3.  Evaluating the Association between Assisted Conception and the Severity of Preeclampsia.

Authors:  Kathryn C Calhoun; Kurt T Barnhart; Michal A Elovitz; Sindhu K Srinivas
Journal:  ISRN Obstet Gynecol       Date:  2011-10-30

4.  Age at menarche, menstrual characteristics, and risk of preeclampsia.

Authors:  Dejene F Abetew; Daniel A Enquobahrie; Michal Dishi; Carole B Rudra; Raymond S Miller; Michelle A Williams
Journal:  ISRN Obstet Gynecol       Date:  2011-12-29

5.  The relationship between metabolic syndrome criteria and preeclampsia in primigravid women.

Authors:  Maryam Kianpour; Shahla Norozi; Parvin Bahadoran; Leila Azadbakht
Journal:  Iran J Nurs Midwifery Res       Date:  2015 Mar-Apr

6.  Metabolic syndrome in preeclampsia women in gorgan.

Authors:  Arash Rafeeinia; Afsaneh Tabandeh; Safoura Khajeniazi; Abdoljalal Marjani
Journal:  Open Biochem J       Date:  2014-12-09

Review 7.  Putative Key Role of Inositol Messengers in Endothelial Cells in Preeclampsia.

Authors:  Sirilaksana Kunjara; Patricia McLean; Laurens Rademacher; Thomas W Rademacher; Fabiana Fascilla; Stefano Bettocchi; Marco Scioscia
Journal:  Int J Endocrinol       Date:  2016-09-21       Impact factor: 3.257

Review 8.  Maternal nutritional risk factors for pre-eclampsia incidence: findings from a narrative scoping review.

Authors:  Mai-Lei Woo Kinshella; Shazmeen Omar; Kerri Scherbinsky; Marianne Vidler; Laura A Magee; Peter von Dadelszen; Sophie E Moore; Rajavel Elango
Journal:  Reprod Health       Date:  2022-09-05       Impact factor: 3.355

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.